We observed no significant difference in the percentage of cells positive for the methyltransferases METTL3 and METTL14 or WTAP, or the demethylases FTO and ALKBH5 between primary AML samples and R/R‐AML samples, but this percentage was significantly greater than that in CR‐AML samples (Figure 1C–G), suggesting that m6A RNA modification enzymes may have prognostic value. The gene discussed is MBD2; the disease is acute myeloid leukemia.